Orthocell Managing Director Paul Anderson said: “This is an important addition to our current global IP portfolio. Not only does it further strengthen our IP position in regenerative medicine products and surgical techniques for soft tissue repair, but it also acts to validate CelGro as a collagen medical device platform, for use across multiple indications including bone, tendons, peripheral nerves and aid in the repair of spinal cord injuries. This comes at a perfect time for the company as we move our products through the registration processes in the US.”
The patent has an expiry date of 12 October 2035. This is the first patent granted in the suture-less repair of tissue patent family. Further patent applications are in progress in all major jurisdictions including US, EU and Japan.
Suture-less repair of soft tissue refers to the method of repairing damaged soft tissue without the use of stitches. Suture-less repair has the potential to greatly improve the efficiency and efficacy of surgical procedures by simplifying techniques, reducing surgery time and reducing the risk of additional trauma to soft tissue through the use of sutures. Therefore, Orthocell’s patented method of suture-less repair provides surgeons with an alternative to direct suture repair of soft tissue defects within tendons, ligaments and nerves.
For example, in the US alone, over 20 million people suffer from peripheral nerve injury as a result of motor vehicle, sporting or work related incidents every year, at an annual cost of approximately US$150 billion. Many of these injuries require surgical nerve reconstruction involving the use of collagen conduits that are secured in place using sutures. To address the disadvantages of suturing, Orthocell developed the CelGro collagen medical device platform with handling characteristics to assist surgeons in performing complex reconstructive surgical procedures and enabling the suture-less repair of soft tissue defects.
CelGro’s nerve addressable market is estimated to be worth more than US$1.1 billion per annum, with approximately 700,000 procedures that could utilize CelGro completed each year. Market growth is expected to be underpinned by the surgeons’ preference for quality and functional bio-absorbable membranes. The company believes CelGro represents a breakthrough in soft tissue reconstruction and offers significant global commercial potential in its existing addressable markets of bone, tendon, nerve and cartilage as well as much wider applications in general surgical and soft tissue reconstructive applications.